Biohaven strikes $795M deal for commercial partner in epilepsy

PartnershipPositive

AI Analysis

Summary

Biohaven has secured a $795 million deal with SK Biopharmaceuticals for global commercial rights to its Kv7 ion channel platform including a late-stage epilepsy drug candidate.

Outcome Details

SK Biopharmaceuticals acquiring global rights to Biohaven's Kv7 ion channel platform

Importance:7/10

Sentiment:

0.70

partnershiplicensingepilepsylate-stage developmentcommercial rights

Related Companies

$GBCYD

Read the original article

Published by Endpoints News on August 26, 2026 5:07 PM

Read Original